Introduction. Currently, monoclonal antibodies directed against key pathogenetic factors of airway inflammation are included in the treatment strategy for patients with severe bronchial asthma (SBA). Given the peculiarities of the course of the disease and the comorbid background of patients of older age groups, the search for additional predictors of the effectiveness of immunobiological therapy is an urgent area of modern research. Purpose of the study: to study the concentrations of interleukin 6 (IL-6) and monocytic chemotactic protein 1 (MCP-1) at dupilumab initiation in patients with SBA older than 60 years. Materials and methods. The study included 148 patients with SBA (females - 57.4%, males - 42.6%), median age of 57 years, of which 47 patients were over 60 years old (females - 61.7%, males - 38.3%), median age - 69 years. All patients were treated with dupilumab. The ACT (Asthma Control Test) results at baseline and at 3 months were taken into account to assess control of asthma symptoms. Statistical processing was performed using the SPSS Statistics 20.0 application package. Results. Serum IL-6 levels in patients over 60 years of age with controlled SBA during dupilumab treatment were 4.51 pg/mL and significantly higher than in the uncontrolled group of 3.11 pg/mL (p = 0.03). Discussion. One of the functions of IL-6 is the regulation of the maturation of plasmocytes from B-lymphocytes and the production of immunoglobulins. The proinflammatory cytokine is a key player in the development of inflamaging and is part of the cytokine profile that determines the secretory phenotype associated with aging (SASP). Conclusion. IL-6 can be considered a promising predictor of dupilumab efficacy in patients with bronchial asthma over 60 years of age.